Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracisAerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatmentActivity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax modelCorrecting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility TestingLevofloxacin cures experimental pneumonic plague in African green monkeys.Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy.Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaCombination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumoniaDifferential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis.Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxBacillus anthracis: interactions with the host and establishment of inhalational anthrax.Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model.Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose.Antimicrobials for bacterial bioterrorism agents.Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule.Antimicrobial susceptibility and the in vitro postantibiotic effects of vancomycin and ciprofloxacin against Bacillus cereus isolates.Incorporating germination-induction into decontamination strategies for bacterial spores.Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?The animal rule: The role of clinical pharmacology in determining an effective dose in humans.Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey.
P2860
Q26771848-870E3CC0-A0A5-4DC6-9B99-66021AA4DE23Q26771850-316B2109-3740-4351-8A06-010D28AFC5B1Q28384759-7F1C6777-A60A-4ACD-BAE3-731754B08575Q28385233-CE79B957-93B1-4B45-BCDE-0E54354A85AEQ33676316-DA9C9934-2261-477C-AE04-73E6FF1DE3F2Q33817871-4C13EC74-7125-48CA-89DE-6BB1C2ED0FBFQ33828874-D68E28EE-4BFF-4D10-992D-EAB3CF41B12BQ34108623-C2DB536D-5730-4B2F-A263-01AE43AE3257Q34146195-B07D439A-EB5B-456E-A5A3-BE028A5B29D2Q34368520-3DEDBAAC-2515-4DCE-8D0C-A5D9A49FC1BCQ34529303-DBD692B0-68E8-4ABB-A20A-8BF6A007B383Q34575393-3BE74B8A-C21B-47C0-82DB-A83E76FF92BDQ34736543-2AB494C1-D5DF-4232-9803-FE0ACDA38836Q35005186-08F61E39-1B35-444E-83D8-53F15E3142DAQ35127882-35D61FE8-47B5-42BD-AA53-10EFAD6B649AQ35647785-CEF70666-6F9B-4DB0-AB85-24DFE41E097EQ35661926-6D68D403-C088-47D3-AB40-4BF6DD4ECE1EQ35666418-FCAD0C7C-60EA-4E12-A3CD-340176666E74Q35759041-1A2CC40B-5DD5-4A88-84C9-EF99A17119D0Q35806278-DE27DE35-23D4-4B61-AD13-462F1A1ACE89Q35912654-76FC10E8-7C98-4DCB-925A-24F3D946B1BAQ36313211-0C47FB29-9FD1-4F35-922B-A5044A726D91Q36870766-7D02DB84-2B50-4B2F-A579-0E990EAA0E06Q36895609-D5A1D9A8-1A53-4203-8F9F-AFA7BD8B40D0Q37033041-42924CED-7CFD-465E-BB09-1470FC423847Q37274688-1CE5B437-D0F6-40CB-AAD8-585435F9BC6FQ37335844-D33BAE7E-038D-438B-819B-B4C254FBF92DQ37409976-C3A052F2-9B9A-4E4E-860A-2934667EC272Q37538531-8C014608-28EC-4CDE-9531-83CF01041810Q37894696-F0F98EBA-2041-41E2-B9CE-4FEF50B52C31Q39181299-A8A599BB-518E-4038-8B6D-A24DC8974A82Q41006434-C22BFAB7-5B1C-4F11-8528-AE86E6B7C04BQ41990890-39DDFFAC-A44C-4943-A42A-508FD7B6B9C0Q43251072-2DDCD681-D41B-4033-826E-224E4A09160CQ46714015-E0DC2341-28C1-4219-93EF-D97296A4FACEQ51794212-3B1965CB-148B-41BD-9895-6C32AFDA1028
P2860
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effective antimicrobial regime ...... and postexposure prophylaxis.
@ast
Effective antimicrobial regime ...... and postexposure prophylaxis.
@en
Effective antimicrobial regime ...... and postexposure prophylaxis.
@nl
type
label
Effective antimicrobial regime ...... and postexposure prophylaxis.
@ast
Effective antimicrobial regime ...... and postexposure prophylaxis.
@en
Effective antimicrobial regime ...... and postexposure prophylaxis.
@nl
prefLabel
Effective antimicrobial regime ...... and postexposure prophylaxis.
@ast
Effective antimicrobial regime ...... and postexposure prophylaxis.
@en
Effective antimicrobial regime ...... and postexposure prophylaxis.
@nl
P2093
P2860
P1476
Effective antimicrobial regime ...... and postexposure prophylaxis.
@en
P2093
Arnold Louie
G L Drusano
Henry Heine
Jennifer Basset
Karen Bush
Lynda Miller
Mark R Deziel
Michael Kelly
William R Byrne
P2860
P304
P356
10.1128/AAC.49.12.5099-5106.2005
P407
P577
2005-12-01T00:00:00Z